Toronto, September 7, 2022 – MORSE Consulting is delighted to announce the addition of 2 new team members, Jaclyn Beca and Sang Mi Lee who will enhance MORSE’s reimbursement expertise into pharmacoeconomics, generation and use of real world evidence (RWE) and development of innovative agreements.
We are at an exciting time in drug discovery and research as new technologies, such as cell and gene therapies, offer opportunities to treat and potentially cure severe and rare conditions. Adding these treatment options to the healthcare system can be highly challenging, given their costs. Financial sustainability continues to be a pressing issue for public and private funding models. There is a critical need for robust pharmacoeconomic analysis to highlight the broader impact of promising innovations on patient outcomes and the healthcare system. In addition, the growing acceptance of RWE provides an extraordinary opportunity for payers and manufacturers to negotiate coverage decisions based on clinical outcomes.
With the addition of Jaclyn Beca, MORSE is delighted to offer strategic pharmacoeconomic advice. Jaclyn is a health economist with more than 12 years of experience supporting the public sector, including provincial governments, cancer agencies and health technology assessment committees. She led the Pharmacoeconomics Research Unit at Cancer Care Ontario and Ontario Health providing objective advice and evidence to guide public drug program policy and planning. She has extensive technical and strategic expertise in pharmacoeconomics and has developed more than 20 submissions to provincial and pan-Canadian drug review processes to address unfunded gaps in the system. Jaclyn has worked closely with CADTH’s pan-Canadian Oncology Drug Review (pCODR) to interpret and improve economic content in the drug review process, and with the pan-Canadian Pharmaceutical Alliance (pCPA) to develop innovative support tools for integrating economic information into negotiations. She has played an active role in exploring and expanding the generation and use of RWE in cancer drug funding as a core member of the Canadian Real-World Evidence for value of Cancer Drugs (CanREValue) Collaboration and has experience developing oncology RWE studies using administrative databases from across Canada. As MORSE Consulting’s Director of Pharmacoeconomics and RWE, Jaclyn will collaborate with clients to deliver strategic advice related to pharmacoeconomic evidence, health technology assessment, development and integration of RWE and overall market access.
Given the promising and complex treatments in development, product listing agreements continue to evolve to meet the needs of payers and manufacturers. There is a growing need for expertise to develop innovative agreement frameworks. With the addition of Sang Mi Lee, MORSE is adding a passionate healthcare leader and pharmacist with over 15 years of unique healthcare experience (public, pharmaceutical industry, consulting, and not-for-profit). She was both Senior Manager and Senior Pharmacist at the pan-Canadian Pharmaceutical Alliance (pCPA) Office, where she led and participated in many negotiations for a broad spectrum of products (biosimilars, immunotherapies, rare diseases and gene therapies) with a variety of agreements (e.g., innovative agreements). In her role with industry, Sang Mi led RWE development and access strategies for the oncology portfolio. As MORSE Consulting’s Director of Innovative Access Solutions, Sang Mi will work closely with clients to develop creative solutions and effective tools to navigate the complex and fast-changing reimbursement environment.
The addition of Jaclyn and Sang Mi further strengthens MORSE’s ability to provide clients with insightful strategies to help them effectively address Canada’s challenging and rapidly evolving reimbursement environment.